Video

Kay Verble Discusses a Study to Characterize Long-Term Survivors of GBM

Author(s):

Kay Verble

Kay Verble discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).

Kay Verble, from the Sontag Foundation and Brain Tumor Network, discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).

Rick Sontag, one of our 2015 GBM Heroes, is an entrepreneur who has worked to improve the lives of patients with GBM and other brain tumors through a multifaceted approach to engaging and supporting the brightest scientific minds in brain cancer research.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Image of woman.
Related Content
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients: © stock.adobe.com.
May 19th 2025

Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma

Spencer Feldman
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
Danyelza is now a recommended treatment in NCCN guidelines for high-risk neuroblastoma: © sudok1 - stock.adobe.com.
May 8th 2025

Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma

Spencer Feldman
Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy: © LukaszDesign - stock.adobe.com
May 5th 2025

AI Tool Predicts Pediatric Glioma Recurrence With Up to 89% Accuracy

Spencer Feldman
An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming single-image methods.
Illustration of brain.
April 30th 2025

Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

Ryan Scott
Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.